AstraZeneca : H1 2022 results presentation

H1 2022 Results

Conference call and webcast for investors and analysts

29 July 2022

Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that global and/or geopolitical events such as the COVID-19 pandemic and the Russia-Ukraine war, may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

2

H1 2022 Results: conference call agenda

CEO Opening Remarks

Financial Results

Oncology

BioPharmaceuticals, Emerging Markets

Rare Disease

Pascal Soriot Chief Executive Officer

Aradhana Sarin Chief Financial Officer

Dave Fredrickson EVP Oncology Business

Susan Galbraith EVP Oncology R&D

Ruud Dobber EVP BioPharmaceuticals Business Mene Pangalos EVP BioPharmaceuticals R&D

Marc Dunoyer Chief Executive Officer Alexion

CEO Closing Remarks, Q&A

Pascal Soriot

Chief Executive Officer

CEO Opening Remarks

Pascal Soriot

Chief Executive Officer

H1 2022: key updates

Progress against our strategic objectives

		Robust growth		Broad-based performance
		Supported by diverse portfolio				Delivering value to patients
•				•
Total Revenue $22.2bn (+48%)	Oncology $7.5bn (+22%)
•	Core EPS $3.61 (+44%)	•	BioPharmaceuticals1 $10.4bn (+31%)
• Increasing 2022 Total Revenue		― CVRM1 $4.6bn (+19%)
	guidance at CER		― R&I $3.0bn (+3%)
• Increased interim dividend to $0.93		― V&I $2.8bn (>2x)
		▪	Vaxzevria2 $1.6bn (+42%)
						▪	Evusheld $914m (n/m)
				•	Rare Disease1 $3.5bn (+10%)

Science-led innovation

Key developments

• Farxiga DELIVER Phase III data readout
• • HFpEF
• Ultomiris CHAMPION-NMOSD Phase III data readout
• • NMOSD
• Imfinzi AEGEAN Phase III pCR data readout
• • NSCLC
• Enhertu DESTINY-Breast04 ASCO presentation
• • HER2-lowbreast cancer
• Enhertu approval (US, EU)
• • HER2-positivebreast cancer (DESTINY-Breast03)
• Tezspire positive CHMP opinion (EU)
• • Severe asthma (NAVIGATOR)
• Ultomiris positive CHMP opinion (EU)
• • gMG (CHAMPION-MG)
• Lynparza positive CHMP opinion (EU)
• • Early breast cancer (OlympiA)

2022 guidance: low twenties % Total Revenue growth (CER) (updated)| mid-to-high twenties % Core EPS growth (CER)

Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) June 2022, unless stated otherwise. 1. Pro forma growth rates reported for Alexion Rare Disease based on prior year historical Alexion reporting and with inclusion of Koselugo and CVRM following Andexxa inclusion; all rates mentioned are pro forma growth rates at CER. 2. Vaxzevria Total Revenue' also includes Collaboration Revenue from sub-licensees that produce and supply AstraZeneca COVID-19 Vaccine under

5 their own trademarks; EPS = earnings per share; n/m = not meaningful; CVRM = Cardiovascular, Renal and Metabolism; R&I = Respiratory and Immunology; V&I = Vaccines and Immune Therapies; HFpEF = heart failure with preserved ejection fraction; NSCLC = non- small cell lung cancer; HER2 = human epidermal growth factor receptor 2; NMOSD = neuromyelitis optica spectrum disorder; pCR = pathologic complete response; CHMP = Committee for Medicinal Products for Human Use; gMG = generalised myasthenia gravis.